•
Apr 25
Medtronic Q4 2025 Earnings Report
Medtronic posted a strong Q4 with solid revenue and earnings growth, supported by double-digit expansion in its Cardiac Ablation and Diabetes businesses.
Key Takeaways
Medtronic delivered a robust Q4 FY25 performance with nearly $9 billion in revenue and strong growth in key franchises such as Cardiac Ablation and Diabetes. The company also announced a strategic plan to spin off its Diabetes business.
Revenue reached $8.93 billion, up from $8.59 billion last year
GAAP EPS surged to $0.82, and Non-GAAP EPS rose to $1.62
Net Income climbed to $1.06 billion, reflecting 62% growth
Medtronic announced intent to spin off its Diabetes business
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Forward Guidance
Medtronic expects FY26 organic revenue growth of approximately 5%, and non-GAAP EPS between $5.50 and $5.60 depending on tariff impacts.
Positive Outlook
- 5% organic revenue growth expected in FY26
- Non-GAAP EPS projected at $5.50 to $5.60
- Continued momentum in key growth drivers
- Leverage on operating profit anticipated
- Robust mitigation plans for potential tariffs
Challenges Ahead
- Tariff risks could impact lower EPS guidance range
- Rising interest expenses forecasted
- Higher tax expenses expected
- Continued restructuring and separation costs
- Global macro uncertainties may weigh on margins
Revenue & Expenses
Visualization of income flow from segment revenue to net income